Publications by authors named "Clara Weil"
Introduction: Disrupted linkage to care is a major barrier to hepatitis C virus (HCV) elimination leading to high attrition rates. This study aimed to describe (1) flow through the HCV care-cascade (2009-2020), and (2) monthly patterns in HCV care during the coronavirus disease 2019 (COVID-19) pandemic (2020) in Israel.
Methods: Data were obtained from Maccabi Healthcare Services, a 2.
Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis.
Adv Ther
December 2024
Article Synopsis
- The study updates findings from the CREST study on the 8-week treatment of glecaprevir/pibrentasvir (GLE/PIB) for patients with chronic hepatitis C and compensated cirrhosis.
- It analyzes 437 patients, showing a high sustained virologic response (SVR12) of 98.9%, especially among those with certain comorbidities and those on other medications.
- The research highlights safety aspects, noting only a small percentage experienced adverse events, and emphasizes variations in healthcare resource use based on patients' employment status and drug use history.
Nirmatrelvir-ritonavir was granted emergency use authorization in Israel in January 2022 to treat high-risk patients with mild-to-moderate COVID-19. The aim of the study was to assess the association between nirmatrelvir-ritonavir treatment and COVID-19-related hospitalization and healthcare resource utilization (HCRU) in a country with a high level of vaccinations compared to patients who were offered treatment and declined. The Maccabi Healthcare Services dataset was used to identify high-risk SARS-CoV-2-positive adults from January to February 2022 who received nirmatrelvir-ritonavir within 5 days of symptom onset (treatment group) or who were offered nirmatrelvir-ritonavir treatment and declined it (reference group).
View Article and Find Full Text PDFArticle Synopsis
- Respiratory syncytial virus (RSV) causes bronchiolitis in infants, and the monoclonal antibody nirsevimab was approved in the EU in 2022, leading to a national immunisation campaign in France starting September 2023.
- A study was conducted in Paris to evaluate nirsevimab's effectiveness in reducing emergency department visits and hospitalisations for bronchiolitis among infants aged 12 months or younger during the RSV season of 2023-24.
- Out of 2786 infants studied, those who received nirsevimab showed lower rates of emergency visits and hospitalisation for bronchiolitis compared to non-vaccinated infants, but data showed that the majority of those
Objective: Vaccination against preventable infections is important for the management of rheumatic diseases (RDs). This study assessed the vaccination coverage and predictors among patients with RDs using real-world data from Israel.
Methods: This retrospective cross-sectional study, based on a Maccabi Healthcare Services database, included adult patients diagnosed with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and systemic lupus erythematosus (SLE), as of April 30, 2019.
Article Synopsis
- New treatments for atopic dermatitis (AD) have emerged over the last decade, yet prevalence and incidence rates remained stable at around 4% and 5.7/1000, respectively, from 2012 to 2021.
- Treatment usage was highest in the first year after diagnosis, with children using more low-potency topical corticosteroids, while adults used more high-potency options.
- A follow-up study showed that only 21.5% of children and 38.3% of adults diagnosed with AD in 2012 had ongoing diagnoses or treatments a decade later, indicating a notable burden of disease and treatment.
Background: There is an unmet need for real-world data regarding laboratory results, co-morbidities, and medication use prior to the first symptoms of amyotrophic lateral sclerosis (ALS). Researchers must identify specific subpopulations at risk for developing ALS and understand pathogenic mechanisms preceding the clinical presentation of ALS as well as possible subclinical disease manifestations.
Objectives: To valuate the role of laboratory results, co-morbidities, and medication use prior to the first symptoms of patients with ALS in Israel so that specific subpopulations at risk for developing ALS can be identified and for possible subclinical disease manifestations.
Treatment options for multiple myeloma (MM) at 1st relapse are expanding. The current study compared common 2nd line regimens administered in a real-world setting. MM patients registered in Maccabi health care services and treated with second line therapy during 2014-2020 were evaluated, analyzing factors affecting time to third line therapy (TT3T).
View Article and Find Full Text PDFMolnupiravir (MOV) was introduced in Israel in January 2022 during the SARS-CoV-2 Omicron surge for high-risk patients contraindicated for nirmatrelvir/ritonavir. This retrospective cohort study aimed to describe characteristics of patients offered COVID-19 antiviral treatment in Maccabi Healthcare Services (antiviral treatment-eligible cohort; = 5596) between 12 January and 28 February 2022, and the subset of these who were dispensed MOV (MOV-treated cohort; = 1147), as well as outcomes following MOV dispensation. Median (interquartile range) age in the antiviral treatment-eligible and MOV-treated cohorts were 70.
View Article and Find Full Text PDFBackground: Patient-reported outcome measures (PROMs) are recommended for assessing patient-centered outcomes in inflammatory bowel disease (IBD). The main aims were to assess the level of participation in an electronic PROM (ePROM) data collection system among patients with IBD, and evaluate reliability and validity of the resulting scores.
Methods: Patients included in the IBD registry of Maccabi Healthcare Services, a state-mandated healthcare provider for over 2.
Background: In recent years, new treatments dedicated to atopic dermatitis (AD) have become available in Israel, including crisaborole, a small molecule with unique benzoxaborole chemistry.
Objective: To describe baseline characteristics, history of AD therapies, and use of health-care services of early crisaborole users in real-world settings.
Methods: A retrospective cohort study was performed using the data of a large health provider in Israel.
Introduction: In clinical trials with hepatitis C virus-infected treatment-naïve (TN) patients with compensated cirrhosis (CC), glecaprevir/pibrentasvir (G/P), a fixed-dose, once-daily, pangenotypic regimen, has demonstrated sustained virologic response at posttreatment Week 12 (SVR12) > 95%. We evaluated the real-world safety and effectiveness of 8-week G/P therapy in TN patients with CC, including certain subgroups of interest.
Methods: The CREST study is a real-world, noninterventional, multicenter study retrospectively assessing data from Canada, Germany, Israel, Italy, and Spain.
Article Synopsis
- - The study analyzed the epidemiology and economic impact of atopic dermatitis (AD) in Israel using a healthcare database from 2008 to 2017, finding an AD incidence of 7.0 per 1,000 person-years and a prevalence of 4.4% overall.
- - Results showed that AD severity was categorized as mild (57.7%), moderate (36.2%), and severe (6.1%), with a notable portion of patients visiting dermatologists and allergists, and hospitalization rates also reported.
- - The findings indicate that individuals with AD incur significantly higher healthcare costs—an increase of 36% for overall costs and 52% for moderate-to-severe cases—compared to controls
The goal of our study was to evaluate the burden of endometriosis in the community by comparing healthcare resource utilization, total direct medical costs, infertility, and comorbidity rates of women with and without a diagnosis of endometriosis. A retrospective case-control study was performed using the databases of a 2.1 million-member nationwide healthcare plan.
View Article and Find Full Text PDFBackground And Aim: In 2017, ustekinumab (UST) was included in Israel's National Basket of Health Services for treatment of biologic-experienced Crohn's disease (CD) patients with moderately to severely active disease. This study aims to provide real-world evidence on persistence and clinical outcomes among early users of UST.
Methods: This retrospective cohort study was conducted using data from Maccabi Healthcare Services (MHS; 2.
Purpose: Congenital cytomegalovirus infection (cCMVi) is the leading cause of nonhereditary sensorineural hearing loss and can cause other long-term neurodevelopmental disabilities; however, data on the economic burden of cCMVi during early childhood are scarce. The primary objective of the study was to describe longitudinal patterns of health care resource utilization (HCRU) and direct medical costs among infants with cCMVi compared to infants unexposed to cCMVi.
Methods: A retrospective cohort study was performed using data on infants born between 2013 and 2017, as captured in the database of Maccabi Healthcare Services, a 2.
Background: Patients with atopic dermatitis (AD) are susceptible to infectious and inflammatory cutaneous comorbidities.
Objective: The aim of the study was to describe the prevalence of cutaneous comorbidities associated with AD, including their relationship with AD severity.
Methods: A retrospective cross-sectional analysis was performed using the Israeli Maccabi Healthcare Services database.
Background: HIV Pre-exposure prophylaxis (PrEP) is the regular use of antiretroviral medication by people who are not infected with HIV to prevent seroconversion. Israel approved PrEP for continuous use in 2017, and Israeli Health Maintenance Organizations (HMO) offered PrEP with a copayment to eligible members.
Methodology: This retrospective cohort study included all people who were dispensed PrEP between September 2017 to June 2019 in the second largest HMO in Israel.
Congenital cytomegalovirus infection (cCMVi) is the leading cause of nonhereditary sensorineural hearing loss among newborns. Women newly acquiring cytomegalovirus infection (CMVi) during pregnancy have the highest risk of vertical transmission. This study aimed to describe the epidemiology of CMVi in pregnancy in a large healthcare database.
View Article and Find Full Text PDFAbout 20% of MM patients have T2DM. We assessed the impact of T2DM/pre-T2DM on MM progression and OS. We collected retrospective data of newly diagnosed MM patients in Maccabi health services, Israel, between 2012 and 2016.
View Article and Find Full Text PDFBackground: Coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccines were shown to be highly efficacious in preventing the disease in randomized controlled trials; nonetheless, evidence on the real-world effectiveness of this vaccine is limited. Study objective was to evaluate the effectiveness of BNT162b2 vaccine in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19-related hospitalization and mortality.
Methods: This historical cohort study included members of a large health provider in Israel that were vaccinated with at least 1 dose of BNT162b2.
This study aims to describe chronic lymphocytic leukemia (CLL) epidemiology, treatment patterns and outcomes in a 2.3-million-member healthcare provider database (Maccabi Healthcare Services, Israel). Newly-diagnosed CLL patients (1999-2017) were followed through 31/3/2018.
View Article and Find Full Text PDFBackground: Survival of patients with multiple myeloma (MM) has improved significantly with access to autologous stem cell transplant (SCT) and new treatments. This study aims to describe epidemiology, treatment patterns, and outcomes of MM in Israel.
Methods: A retrospective observational study was conducted in Maccabi Healthcare Services, a 2-million-member nationwide health plan in Israel.
Problem: The aim of this study was to investigate the prevalence of and the association between endometriosis, fibromyalgia, and autoimmune disease (AID) in a large population database and to describe healthcare resource utilization (HCRU) in affected women.
Methods: A retrospective cross-sectional study was performed using the computerized databases of Maccabi Healthcare Services (MHS), a 2.1-million-member healthcare plan in Israel.